Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies

PMID: 24784346
Journal: Expert review of clinical immunology (volume: 10, issue: 6, Expert Rev Clin Immunol 2014 Jun;10(6):705-11)
Published: 2014-05-02

Coosemans A, Vergote I, Van Gool SW


Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms‘ tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy.